BioStem Technologies exceeded Q1 earnings estimates with EPS of 0.30 and revenue of $74.49M.
BioStem Technologies (BSEM) reported Q1 earnings, exceeding expectations with EPS of 0.30 vs. 0.12 estimate and revenue of $74.49M vs. $43.99M estimate. Following the announcement, shares increased by 0.50 to $12.50 on a volume of 65,600 shares, compared to the average of 25,206. The life sciences company focuses on pharmaceutical and regenerative medicine products and services.
August 13, 2024
3 Articles